| Status | Study |
| Recruiting |
Study Name: Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity Condition: Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic) Leptin Receptor Date: 2017-01-03 Interventions: Drug: Setmelanotide RM-493 once daily subcutaneous injection |
| Recruiting |
Study Name: Clinical Study of a Single Ciliopathy: Alström Syndrome Condition: Alström Syndrome (ALMS) Date: 2016-08-19 |
| Recruiting |
Study Name: Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome Condition: Inflammation and Fibrosis Diabetes Date: 2016-02-25 Interventions: Drug: PBI-4050 Four 200 mg capsules (800 mg total) administered orally, once daily. |
| Active, not recruiting |
Study Name: Clinical and Molecular Investigations Into Ciliopathies Condition: Autosomal Recessive Polycystic Kidney Disease Congenital Hepatic Fibrosis Date: 2003-09-10 |